Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC221 in mild COVID-19
NCT04940182Phase 3Completed
- Sponsor
- RSV Therapeutics LLC
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aterixen in coronavirus disease 2019 (COVID-19), sponsored by RSV Therapeutics LLC. Started Jun 2021; status: completed.
02
Drugs
aterixen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04940182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940182.